Shared on02 Sep 25Fair value Increased 7.75%
BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.